Published in PLoS One on February 23, 2015
First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis | NCT00875446
Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials. Front Neurol (2017) 0.75
A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med (1994) 8.82
From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci (2001) 6.48
Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming. Comput Methods Programs Biomed (2004) 5.13
Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther (1979) 5.13
Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci (2004) 4.28
Diagnosing model diagnostics. Clin Pharmacol Ther (2007) 4.17
Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet (1996) 4.11
Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol (2000) 2.61
Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res (2007) 2.51
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev (2012) 2.49
Nogo and axon regeneration. Curr Opin Neurobiol (2004) 2.48
The Hill equation: a review of its capabilities in pharmacological modelling. Fundam Clin Pharmacol (2008) 2.44
Automated covariate model building within NONMEM. Pharm Res (1998) 2.32
Functions of Nogo proteins and their receptors in the nervous system. Nat Rev Neurosci (2010) 2.08
Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J (2009) 1.48
Three new residual error models for population PK/PD analyses. J Pharmacokinet Biopharm (1995) 1.37
Population pharmacokinetics: theory and practice. Br J Clin Pharmacol (1991) 1.29
Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis. Neurobiol Dis (2002) 1.17
Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. Ann Neurol (2005) 1.11
Palliative care in amyotrophic lateral sclerosis. Neurol Clin (2001) 1.10
Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn (2013) 0.98
More efficient clinical trials through use of scientific model-based statistical tests. Clin Pharmacol Ther (2002) 0.96
The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure. Curr Med Chem (2007) 0.96
Motor neuron disease: the bare essentials. Pract Neurol (2009) 0.90
Muscle gene expression is a marker of amyotrophic lateral sclerosis severity. Neurodegener Dis (2011) 0.88
Applications of laser scanning cytometry in immunohistochemistry and routine histopathology. Toxicol Pathol (2008) 0.84
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial. PLoS One (2014) 0.81
Preclinical applications of quantitative imaging cytometry to support drug discovery. Methods Cell Biol (2011) 0.77